FMP
Rubius Therapeutics, Inc.
RUBY
NASDAQ
Inactive Equity
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
0.057 USD
0.0015 (2.63%)
Overall Rating
Discounted Cash Flow
Return on Equity
Return on Assets
Debt to Equity
Price to Earnings
Price to Book
We are unable to load the data!
We are unable to load the data!